Market capitalization | €1.05b |
Enterprise Value | €3.19b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 7.36 |
EV/Sales (TTM) EV/Sales | 0.43 |
P/S ratio (TTM) P/S ratio | 0.14 |
P/B ratio (TTM) P/B ratio | 2.48 |
Sales growth (TTM) Sales growth | 1.34% |
Turnover (TTM) Turnover | €7.45b |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
5 Analysts have issued a Fincantieri forecast:
5 Analysts have issued a Fincantieri forecast:
Dec '23 |
+/-
%
|
||
Turnover | 7,448 7,448 |
1%
1%
|
|
Gross income | 485 485 |
38%
38%
|
|
EBITDA | 212 212 |
164%
164%
|
EBIT (operating result) EBIT | -21 -21 |
86%
86%
|
Net profit | -53 -53 |
83%
83%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Fincantieri SpA engages in the design and construction of cruise ships, military ships, auxiliary and special submarines, and offshore support vessels. It operates through the following business segments: Shipbuilding; Offshore; and Equipment, Systems, and Services. The Shipbuilding segment involves in the production, repair, and conversion of cruise ships, ferries, naval vessels, and mega-yachts. The Offshore segment provides the design and construction of support vessels for the oil and gas exploration and production market, as well as the services and production of electronic systems, power and automation solutions, pipe systems, electrical installations, and accommodation for such support vessels. The Equipment, Systems and Services segment engages in the manufacture of mechanical products and the provision of after-sales services for the delivered ships. The company was founded on December 29, 1959 and is headquartered in Trieste, Italy.
Head office | Italy |
CEO | Pierroberto Gallia |
Employees | 21,215 |
Founded | 1996 |
Website | www.fincantieri.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.